IL177611A - Aβ antibody preparation process - Google Patents
Aβ antibody preparation processInfo
- Publication number
- IL177611A IL177611A IL177611A IL17761106A IL177611A IL 177611 A IL177611 A IL 177611A IL 177611 A IL177611 A IL 177611A IL 17761106 A IL17761106 A IL 17761106A IL 177611 A IL177611 A IL 177611A
- Authority
- IL
- Israel
- Prior art keywords
- antibody
- preparing
- abeta
- free
- low levels
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54676404P | 2004-02-23 | 2004-02-23 | |
| PCT/US2005/005198 WO2005082939A2 (en) | 2004-02-23 | 2005-02-17 | Anti-abeta antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL177611A0 IL177611A0 (en) | 2006-12-10 |
| IL177611A true IL177611A (en) | 2013-05-30 |
Family
ID=34910810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL177611A IL177611A (en) | 2004-02-23 | 2006-08-21 | Aβ antibody preparation process |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20070190046A1 (enExample) |
| EP (1) | EP1720909B1 (enExample) |
| JP (1) | JP4851348B2 (enExample) |
| KR (2) | KR100889430B1 (enExample) |
| CN (1) | CN1922209B (enExample) |
| AT (1) | ATE534667T1 (enExample) |
| AU (1) | AU2005217596B2 (enExample) |
| BR (1) | BRPI0507856A (enExample) |
| CA (1) | CA2556436C (enExample) |
| CY (1) | CY1112162T1 (enExample) |
| DK (1) | DK1720909T3 (enExample) |
| EA (1) | EA009872B1 (enExample) |
| ES (1) | ES2375627T3 (enExample) |
| IL (1) | IL177611A (enExample) |
| NO (1) | NO20064239L (enExample) |
| PL (1) | PL1720909T3 (enExample) |
| PT (1) | PT1720909E (enExample) |
| SI (1) | SI1720909T1 (enExample) |
| UA (1) | UA93181C2 (enExample) |
| WO (1) | WO2005082939A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| SG10201706600VA (en) | 2005-11-30 | 2017-09-28 | Abbvie Inc | Monoclonal antibodies and uses thereof |
| KR20080090408A (ko) | 2005-11-30 | 2008-10-08 | 아보트 러보러터리즈 | 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법 |
| JP5419131B2 (ja) | 2005-12-12 | 2014-02-19 | エーシー イミューン ソシエテ アノニム | 治療的特性を有するβ１〜４２特異的モノクローナル抗体 |
| TWI551607B (zh) | 2006-07-14 | 2016-10-01 | Ａｃ免疫公司 | 人類化抗體 |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| HRP20140049T1 (hr) | 2007-01-05 | 2014-02-28 | University Of Zürich | Anti beta-amiloid antitijela i njihova upotreba |
| US8906367B2 (en) | 2007-01-05 | 2014-12-09 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
| AU2008204335B2 (en) | 2007-01-11 | 2013-06-13 | Michael Bacher | Diagnosis and treatment of Alzheimer's and other neurodementing diseases |
| WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) * | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| CA2701793C (en) | 2007-10-05 | 2017-04-25 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
| RU2542967C2 (ru) * | 2007-10-05 | 2015-02-27 | Дженентек, Инк. | Применение антитела против амилоида бета при глазных заболеваниях |
| KR20110089185A (ko) | 2008-11-25 | 2011-08-04 | 바이오겐 아이덱 엠에이 인코포레이티드 | 신경계 세포의 생존을 촉진하기 위한 ｄｒ６ 및 ｐ７５ 길항제의 용도 |
| WO2010069603A1 (en) | 2008-12-19 | 2010-06-24 | Neurimmune Therapeutics Ag | Human anti-alpha-synuclein autoantibodies |
| JP2013510871A (ja) | 2009-11-12 | 2013-03-28 | ジェネンテック， インコーポレイテッド | 樹状突起棘の密度を促す方法 |
| EP2558494B1 (en) | 2010-04-15 | 2018-05-23 | AbbVie Inc. | Amyloid-beta binding proteins |
| CN103179981B (zh) | 2010-07-30 | 2017-02-08 | Ac免疫有限公司 | 安全和功能性的人源化抗β‑淀粉样蛋白抗体 |
| LT3042917T (lt) * | 2010-08-12 | 2018-05-10 | Eli Lilly And Company | Antikūnai prieš n3pglu beta amiloidinį peptidą ir jų panaudojimas |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| LT2723379T (lt) | 2011-06-23 | 2018-10-25 | Biogen International Neuroscience Gmbh | Anti-alfa sinukleiną rišančios molekulės |
| JP6486272B2 (ja) | 2012-09-07 | 2019-03-20 | マサチューセッツ・アイ・アンド・イア・インファーマリー | 有毛細胞および／または支持細胞再生のための方法および組成物 |
| EP3970725B1 (en) | 2012-09-07 | 2025-08-20 | Massachusetts Eye & Ear Infirmary | A gamma secretase inhibitor for treating hearing loss |
| CN105722532A (zh) | 2013-09-13 | 2016-06-29 | 豪夫迈·罗氏有限公司 | 包含纯化的重组多肽的方法和组合物 |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| EP3458076A4 (en) | 2016-05-16 | 2020-01-22 | The General Hospital Corporation | HUMAN RESPIRATORY STEM CELLS IN BREEDING LUNG EPITHEL |
| US20210355138A1 (en) * | 2016-08-11 | 2021-11-18 | Eli Lilly And Company | Aminothiazinies and their use as bace1 inhibitors |
| SI3672631T1 (sl) | 2017-08-22 | 2023-06-30 | Biogen Ma Inc. | Farmacevtski sestavki, ki vsebujejo protitelesa proti beta amiloidu |
| TWI843040B (zh) | 2021-01-11 | 2024-05-21 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| EP4472679A1 (en) | 2022-02-03 | 2024-12-11 | Eli Lilly and Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2272305A1 (en) | 1996-12-23 | 1998-07-02 | Elan Pharmaceuticals, Inc. | Cycloalkyl, lactam, lactone and related compounds as .beta.-amyloid peptide release inhibitors |
| US6518011B1 (en) * | 1999-01-13 | 2003-02-11 | Bristol-Myers Squibb Company | Method for screening compounds to identify beta-amyloid production modulators |
| KR100767146B1 (ko) * | 2000-02-24 | 2007-10-15 | 워싱톤 유니버시티 | Ａβ 펩티드를 격리시키는 인간화 항체 |
| CA2406383A1 (en) * | 2000-04-13 | 2001-10-25 | Mayo Foundation For Medical Education And Research | A.beta.42 lowering agents |
| PE20020574A1 (es) * | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| ATE420114T1 (de) * | 2001-04-30 | 2009-01-15 | Lilly Co Eli | Humanisierte antikörper die das beta-amyloid peptid erkennen& x9; |
-
2005
- 2005-02-17 AU AU2005217596A patent/AU2005217596B2/en not_active Ceased
- 2005-02-17 EP EP05723280A patent/EP1720909B1/en not_active Expired - Lifetime
- 2005-02-17 KR KR1020067016812A patent/KR100889430B1/ko not_active Expired - Fee Related
- 2005-02-17 UA UAA200609258A patent/UA93181C2/ru unknown
- 2005-02-17 KR KR1020087031635A patent/KR20090005410A/ko not_active Ceased
- 2005-02-17 US US10/590,411 patent/US20070190046A1/en not_active Abandoned
- 2005-02-17 BR BRPI0507856-3A patent/BRPI0507856A/pt not_active IP Right Cessation
- 2005-02-17 JP JP2006554230A patent/JP4851348B2/ja not_active Expired - Fee Related
- 2005-02-17 DK DK05723280.3T patent/DK1720909T3/da active
- 2005-02-17 AT AT05723280T patent/ATE534667T1/de active
- 2005-02-17 CA CA2556436A patent/CA2556436C/en not_active Expired - Fee Related
- 2005-02-17 CN CN2005800056858A patent/CN1922209B/zh not_active Expired - Fee Related
- 2005-02-17 WO PCT/US2005/005198 patent/WO2005082939A2/en not_active Ceased
- 2005-02-17 EA EA200601545A patent/EA009872B1/ru not_active IP Right Cessation
- 2005-02-17 PL PL05723280T patent/PL1720909T3/pl unknown
- 2005-02-17 PT PT05723280T patent/PT1720909E/pt unknown
- 2005-02-17 SI SI200531422T patent/SI1720909T1/sl unknown
- 2005-02-17 ES ES05723280T patent/ES2375627T3/es not_active Expired - Lifetime
-
2006
- 2006-08-21 IL IL177611A patent/IL177611A/en not_active IP Right Cessation
- 2006-09-19 NO NO20064239A patent/NO20064239L/no not_active Application Discontinuation
-
2011
- 2011-12-21 CY CY20111101276T patent/CY1112162T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UA93181C2 (ru) | 2011-01-25 |
| SI1720909T1 (sl) | 2012-01-31 |
| ES2375627T3 (es) | 2012-03-02 |
| CA2556436C (en) | 2014-04-01 |
| CN1922209B (zh) | 2012-09-05 |
| CN1922209A (zh) | 2007-02-28 |
| JP4851348B2 (ja) | 2012-01-11 |
| JP2008500279A (ja) | 2008-01-10 |
| BRPI0507856A (pt) | 2007-07-10 |
| EP1720909B1 (en) | 2011-11-23 |
| EA200601545A1 (ru) | 2007-02-27 |
| EA009872B1 (ru) | 2008-04-28 |
| KR100889430B1 (ko) | 2009-03-23 |
| PL1720909T3 (pl) | 2012-04-30 |
| ATE534667T1 (de) | 2011-12-15 |
| KR20060126785A (ko) | 2006-12-08 |
| AU2005217596B2 (en) | 2012-01-19 |
| PT1720909E (pt) | 2011-12-23 |
| DK1720909T3 (da) | 2012-01-30 |
| CA2556436A1 (en) | 2005-09-09 |
| WO2005082939A2 (en) | 2005-09-09 |
| WO2005082939A3 (en) | 2005-10-27 |
| IL177611A0 (en) | 2006-12-10 |
| NO20064239L (no) | 2006-11-20 |
| KR20090005410A (ko) | 2009-01-13 |
| US20070190046A1 (en) | 2007-08-16 |
| EP1720909A2 (en) | 2006-11-15 |
| AU2005217596A1 (en) | 2005-09-09 |
| CY1112162T1 (el) | 2015-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL177611A (en) | Aβ antibody preparation process | |
| PH12015501848A1 (en) | Binding agents | |
| MY174493A (en) | Binding agents | |
| MY161909A (en) | Anti-her3 antibodies and uses thereof | |
| IL244803B (en) | Human anti-beta antibodies and their use | |
| TW200745334A (en) | Compositions and methods for producing a composition | |
| SG162687A1 (en) | Caustic stable chromatography ligands | |
| MX2009006594A (es) | Formulaciones de ph regulado y estables que contienen polipeptidos. | |
| MX2009012949A (es) | Anticuerpos humanizados que enlazan a ab (1-42) globulomero y usos de los mismos. | |
| IN2012DN05237A (enExample) | ||
| MX2011010012A (es) | NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS. | |
| MY147217A (en) | Antibody molecules having specificity for human il-06 | |
| MX2010001237A (es) | Nuevos anticuerpos. | |
| NZ609501A (en) | Antibodies to notum pectinacetylesterase | |
| EA200800601A1 (ru) | Связывающие fas антитела | |
| SG149892A1 (en) | Identification of novel ige epitopes | |
| NO20060535L (no) | Aztreonam-L-lysin og fremgangsmater for fremstilling av dette | |
| EA200601743A1 (ru) | Выделенный полипептид реналазы и его применение | |
| MX2009008754A (es) | Anticuerpos novedosos contra igf-1r. | |
| EP1885867A4 (en) | NEW PROCEDURES | |
| BRPI0406970A (pt) | Modificação cristalina de um complexo de manganês | |
| UA99579C2 (ru) | АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С Tau, ФОСФОРИЛИРОВАННЫМ ПО СЕРИНУ 422 (pS422), ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ ТАУПАТИИ | |
| MY142798A (en) | Methods for preventing glyconoylation of proteins | |
| UA97231C2 (ru) | Изолированное антитело, которое специфически связывается с il-6, композиция, которая его содержит, и его применение | |
| ATE527354T1 (de) | Diabetogene epitope |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |